

Guocai Zhong

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6037131/publications.pdf>

Version: 2024-02-01

16
papers

2,486
citations

687363

13
h-index

940533

16
g-index

20
all docs

20
docs citations

20
times ranked

3680
citing authors

#	ARTICLE	IF	CITATIONS
1	Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus. <i>ELife</i> , 2012, 1, e00049.	6.0	1,621
2	Molecular Determinants of Hepatitis B and D Virus Entry Restriction in Mouse Sodium Taurocholate Cotransporting Polypeptide. <i>Journal of Virology</i> , 2013, 87, 7977-7991.	3.4	167
3	SARS-CoV-2 and Three Related Coronaviruses Utilize Multiple ACE2 Orthologs and Are Potently Blocked by an Improved ACE2-Ig. <i>Journal of Virology</i> , 2020, 94, .	3.4	100
4	Nonmuscle Myosin Heavy Chain IIA Is a Critical Factor Contributing to the Efficiency of Early Infection of Severe Fever with Thrombocytopenia Syndrome Virus. <i>Journal of Virology</i> , 2014, 88, 237-248.	3.4	93
5	Rational design of aptazyme riboswitches for efficient control of gene expression in mammalian cells. <i>ELife</i> , 2016, 5, .	6.0	74
6	A reversible RNA on-switch that controls gene expression of AAV-delivered therapeutics in vivo. <i>Nature Biotechnology</i> , 2020, 38, 169-175.	17.5	60
7	Cpf1 proteins excise CRISPR RNAs from mRNA transcripts in mammalian cells. <i>Nature Chemical Biology</i> , 2017, 13, 839-841.	8.0	58
8	Sodium Taurocholate Cotransporting Polypeptide Mediates Woolly Monkey Hepatitis B Virus Infection of Tupaia Hepatocytes. <i>Journal of Virology</i> , 2013, 87, 7176-7184.	3.4	57
9	Potent prophylactic and therapeutic efficacy of recombinant human ACE2-Fc against SARS-CoV-2 infection in vivo. <i>Cell Discovery</i> , 2021, 7, 65.	6.7	51
10	Mutation Y453F in the spike protein of SARS-CoV-2 enhances interaction with the mink ACE2 receptor for host adaption. <i>PLoS Pathogens</i> , 2021, 17, e1010053.	4.7	43
11	Conditional Regulation of Gene Expression by Ligand-Induced Occlusion of a MicroRNA Target Sequence. <i>Molecular Therapy</i> , 2018, 26, 1277-1286.	8.2	22
12	Characterization of SARS-CoV-2 Variants B.1.617.1 (Kappa), B.1.617.2 (Delta), and B.1.618 by Cell Entry and Immune Evasion. <i>MBio</i> , 2022, 13, e0009922.	4.1	22
13	A more efficient CRISPR-Cas12a variant derived from Lachnospiraceae bacterium MA2020. <i>Molecular Therapy - Nucleic Acids</i> , 2021, 24, 40-53.	5.1	19
14	Potent and Specific Inhibition of NTCP-Mediated HBV/HDV Infection and Substrate Transporting by a Novel, Oral-Available Cyclosporine A Analogue. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 543-565.	6.4	12
15	Selection of High-Affinity RNA Aptamers That Distinguish between Doxycycline and Tetracycline. <i>Biochemistry</i> , 2020, 59, 3473-3486.	2.5	10
16	Reprogramming of the heavy-chain CDR3 regions of a human antibody repertoire. <i>Molecular Therapy</i> , 2022, 30, 184-197.	8.2	8